| Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome |
61 |
| Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations |
24 |
| Pathophysiology of systemic sclerosis: current understanding and new insights |
22 |
| The nocebo effect: a clinical challenge in the era of biosimilars |
19 |
| Pyoderma gangrenosum: a review of pathogenesis and treatment |
17 |
| Quality of life in psoriatic arthritis |
16 |
| Immunogenicity of biologic therapies: causes and consequences |
14 |
| An update on generalized pustular psoriasis |
13 |
| Tofacitinib for the treatment of psoriasis and psoriatic arthritis |
13 |
| Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018 |
13 |
| Mortality in systemic lupus erythematosus: causes, predictors and interventions |
13 |
| Anti-DFS70 antibodies: an update on our current understanding and their clinical usefulness |
12 |
| STAT1 and STAT3 mutations: important lessons for clinical immunologists |
12 |
| An update on pathogenesis of psoriatic arthritis and potential therapeutic targets |
11 |
| Radiographic progression in non-radiographic axial spondyloarthritis |
10 |
| Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases |
10 |
| Clinically-useful serum biomarkers for diagnosis and prognosis of sarcoidosis |
10 |
| Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review |
9 |
| CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience |
9 |
| Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders? |
9 |
| Current and emerging treatment options for autoimmune hemolytic anemia |
9 |
| Factors affecting quality of life in patients with systemic lupus erythematosus: important considerations and potential interventions |
9 |
| CD40 ligand deficiency: treatment strategies and novel therapeutic perspectives |
9 |
| The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond |
9 |
| Tocilizumab for the treatment of giant cell arteritis |
8 |
| Upadacitinib for the treatment of rheumatoid arthritis |
8 |
| New frontiers in precision medicine for sepsis-induced immunoparalysis |
8 |
| Anakinra for the treatment of adult-onset Still's disease |
8 |
| Stress, mindfulness, and the allergic patient |
8 |
| Tofacitinib for the treatment of ulcerative colitis |
8 |
| Pathogenesis of adult onset still's disease: current understanding and new insights |
8 |
| An update on the pathogenesis of hidradenitis suppurativa: implications for therapy |
8 |
| Cannabis allergy: what the clinician needs to know in 2019 |
8 |
| The role of epigenetics in the development of childhood asthma |
7 |
| Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease |
7 |
| Medical cannabis and cannabinoids in rheumatology: where are we now? |
7 |
| The association between early life antibiotic use and allergic disease in young children: recent insights and their implications |
7 |
| Cigarette smoking and the pathogenesis of systemic lupus erythematosus |
7 |
| Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update |
7 |
| Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases |
7 |
| Adherence to medication in children and adolescents with asthma: methods for monitoring and intervention |
7 |
| Pain and affective distress in arthritis: relationship to immunity and inflammation |
7 |
| Prediction of response to methotrexate in rheumatoid arthritis |
6 |
| Additive immunosuppressive effect of leflunomide and hydroxychloroquine supports rationale for combination therapy for Sjogren's syndrome |
6 |
| An update on cutaneous complications of permanent tattooing |
6 |
| Belatacept in kidney transplantation and its limitations |
6 |
| Recent advances in the diagnosis of allergic rhinitis |
6 |
| Taking a prebiotic approach to early immunomodulation for allergy prevention |
6 |
| Allergen immunotherapy in atopic dermatitis |
6 |
| The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target |
6 |
